ZYN002
ZYN2-CL-031
Phase 2 small_molecule completed
Quick answer
ZYN002 for 22Q11.2 Deletion Syndrome is a Phase 2 program (small_molecule) at Harmony Biosciences Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Harmony Biosciences Holdings
- Indication
- 22Q11.2 Deletion Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed